MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment

Bosch F. X. Ribes J. Diaz M. Cleries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127, S5–S16 (2004). DOI: 10.1053/j.gastro.2004.09.011.

Yeh C. N. Chen M. F. Lee W. C. Jeng L. B. Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: Univariate and multivariate analysis. J Surg Oncol 81, 195–202 (2002). DOI: 10.1002/jso.10178.

Lee H. S. Kim J. S. Choi I. J. Chung J. W. Park J. H. Kim C. Y. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 79, 2087–2094 (1997). DOI: 10.1002/(SICI)1097–0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M.

Llovet J. M. Ricci S. Mazzaferro V. Hilgard P. Gane E. Blanc J. F. de Oliveira A. C. Santoro A. Raoul J. L. Forner A. Schwartz M. Porta C. Zeuzem S. Bolondi L. Greten T. F. Galle P. R. Seitz J. F. Borbath I. Haussinger D. Giannaris T. Shan M. Moscovici M. Voliotis D. Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359, 378–390 (2008). DOI: 10.1056/NEJMoa0708857.

Liu L. Cao Y. Chen C. Zhang X. McNabola A. Wilkie D. Wilhelm S. Lynch M. Carter C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66, 11851–11858 (2006). DOI: 10.1158/0008-5472.

Vatsyayan R. Singhal J. Nagaprashantha L. D. Awasthi S. Singhal S. S. Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma. Mol Carcinog (2011). DOI: 10.1002/mc.20875.

Yekta S. Shih I. H. Bartel D. P. MicroRNA-directed cleavage of HOXB8 mRNA. Science 304, 594–596 (2004). DOI: 10.1126/science.1097434.

Bartel D. P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004). DOI: 10.1016/S0092–8674(04)00045-5.

Griffiths-Jones S. The microRNA registry. Nucleic Acids Res 32, D109–111 (2004). DOI: 10.1093/nar/gkh023.

Qin W. Shi Y. Zhao B. Yao C. Jin L. Ma J. Jin Y. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PloS One 5, e9429 (2010). DOI:10.1371/journal.pone.0009429.

Lytle J. R. Yario T. A. Steitz J. A. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR. Proceedings of the National Academy of Sciences of the United States of America 104, 9667–9672 (2007). DOI: 10.1073/pnas.0703820104.

Lewis B. P. Burge C. B. Bartel D. P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005). DOI: 10.1016/j.cell.2004.12.035.

Lu J. Getz G. Miska E. A. Alvarez-Saavedra E. Lamb J. Peck D. Sweet-Cordero A. Ebert B. L. Mak R. H. Ferrando A. A. Downing J. R. Jacks T. Horvitz H. R. Golub T. R. MicroRNA expression profiles classify human cancers. Nature 435, 834–838 (2005). DOI: 10.1038/nature03702.

Gramantieri L. Ferracin M. Fornari F. Veronese A. Sabbioni S. Liu C. G. Calin G. A. Giovannini C. Ferrazzi E. Grazi G. L. Croce C. M. Bolondi L. Negrini M. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67, 6092–6099 (2007). DOI: 10.1158/0008–5472.CAN-06-4607.

Fornari F. Gramantieri L. Giovannini C. Veronese A. Ferracin M. Sabbioni S. Calin G. A. Grazi G. L. Croce C. M. Tavolari S. Chieco P. Negrini M. Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69, 5761–5767 (2009). DOI: 10.1158/0008–5472.CAN-08-4797.

Bai S. Nasser M. W. Wang B. Hsu S. H. Datta J. Kutay H. Yadav A. Nuovo G. Kumar P. Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284, 32015–32027 (2009). DOI: 10.1074/jbc.M109.016774.

Meng F. Henson R. Lang M. Wehbe H. Maheshwari S. Mendell J. T. Jiang J. Schmittgen T. D. Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113–2129 (2006). DOI: 10.1053/j.gastro.2006.02.057.

Moriyama T. Ohuchida K. Mizumoto K. Yu J. Sato N. Nabae T. Takahata S. Toma H. Nagai E. Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8, 1067–1074 (2009). DOI: 10.1158/1535–7163.MCT-08-0592.

Park J. K. Lee E. J. Esau C. Schmittgen T. D. Antisense inhibition of microRNA-21 or −221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38, e190–199 (2009). DOI: 10.1097/MPA.0b013e3181ba82e1.

Shimizu S. Takehara T. Hikita H. Kodama T. Miyagi T. Hosui A. Tatsumi T. Ishida H. Noda T. Nagano H. Doki Y. Mori M. Hayashi N. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 52, 698–704 (2010). DOI: 10.1016/j.jhep.2009.12.024.

Nakatani F. Ferracin M. Manara M. C. Ventura S. Del Monaco V. Ferrari S. Alberghini M. Grilli A. Knuutila S. Schaefer K. L. Mattia G. Negrini M. Picci P. Serra M. Scotlandi K. miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol 226, 796–805 (2012). DOI: 10.1002/path.3007.

Fujita Y. Kojima K. Hamada N. Ohhashi R. Akao Y. Nozawa Y. Deguchi T. Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377, 114–119 (2008). DOI: 10.1016/j.bbrc.2008.09.086.

Kojima K. Fujita Y. Nozawa Y. Deguchi T. Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70, 1501–1512 (2010). DOI: 10.1002/pros.21185.

Ji Q. Hao X. Meng Y. Zhang M. Desano J. Fan D. Xu L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8, 266 (2008). DOI: 10.1186/1471–2407–8-266.

Vinall R. L. Ripoll A. Z. Wang S. Pan C. X. deVere White R. W. MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130, 2526–2538 (2012). DOI: 10.1002/ijc.26256.

Zekri A. R. Bahnassy A. A. Abdel-Wahab S. A. Khafagy M. M. Loutfy S. A. Radwan H. Shaarawy S. M. Expression of pro- and anti-inflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCV-genotype-4. J Gastroenterol Hepatol 24, 416–428 (2009). DOI: 10.1111/j.1440-1746.2008.05699.x.

Hung J. H. Teng Y. N. Wang L. H. Su I. J. Wang C. C. Huang W. Lee K. H. Lu K. Y. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells. PLoS One 6, e28977 (2011). DOI: 10.1371/journal.pone.0028977.

Budhu A. Jia H. L. Forgues M. Liu C. G. Goldstein D. Lam A. Zanetti K. A. Ye Q. H. Qin L. X. Croce C. M. Tang Z. Y. Wang X. W. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47, 897–907 (2008). DOI: 10.1002/hep.22160.

Bommer G. T. Gerin I. Feng Y. Kaczorowski A. J. Kuick R. Love R. E. Zhai Y. Giordano T. J. Qin Z. S. Moore B. B. MacDougald O. A. Cho K. R. Fearon E. R. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17, 1298–1307 (2007). DOI: 10.1016/j.cub.2007.06.068.

Takehara T. Liu X. Fujimoto J. Friedman S. L. Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34, 55–61 (2001). DOI: 10.1053/jhep.2001.25387.

Xia L. Zhang D. Du R. Pan Y. Zhao L. Sun S. Hong L. Liu J. Fan D. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 123, 372–379 (2008). DOI: 10.1002/ijc.23501.

Tryndyak V. P. Ross S. A. Beland F. A. Pogribny I. P. Down-regulation of the microRNAs miR-34a, miR-127, and miR-200b in rat liver during hepatocarcinogenesis induced by a methyl-deficient diet. Mol Carcinog 48, 479–487 (2009). DOI: 10.1002/mc.20484.

Li N. Fu H. Tie Y. Hu Z. Kong W. Wu Y. Zheng X. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275, 44–53 (2009). DOI: 10.1016/j.canlet.2008.09.035.

Pogribny I. P. Tryndyak V. P. Boyko A. Rodriguez-Juarez R. Beland F. A. Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutation Research 619, 30–37 (2007). DOI: 10.1016/j.mrfmmm.2006.12.006.

Pineau P. Volinia S. McJunkin K. Marchio A. Battiston C. Terris B. Mazzaferro V. Lowe S. W. Croce C. M. Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107, 264–269 (2010). DOI: 10.1073/pnas.0907904107.

Nalls D. Tang S. N. Rodova M. Srivastava R. K. Shankar S. Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6, e24099 (2011). DOI: 10.1371/journal.pone.0024099.

Kastl L. Brown I. Schofield A. C. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131, 445–454 (2012). DOI: 10.1007/s10549–011–1424-3.